FPT
8.4.2022 11:49:11 CEST | Business Wire | Press release
In the Annual General Meeting 2022 (AGM 2022), FPT Corporation (FPT) has announced its goal to be among the Top 50 global end-to-end digital transformation service providers by 2030 and plans to continue working toward the long-term goal of becoming a standard-bearing digital enterprise.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220408005158/en/
Last year marked FPT’s effort to “rebirth” as the number of projects worth over 5 million USD increased by 111%. The firm’s global revenue in 2021 reached 1.6 billion USD, which grew nearly 20% year on. Foreign markets also recorded positive growth, including the Americas (+52%) and APAC (+27%).
FPT has pledged to become a strategic partner for businesses worldwide. In the 2022 - 2024 period, FPT shall continue to pursue this orientation, with the core mission of “Promoting rapid growth, developing new technology products, and providing digital transformation services on a large scale”, as mentioned by FPT Chairman Truong Gia Binh in FPT’s 2021 Annual Report.
To achieve this mission, Vietnam’s largest IT services provider plans to continue projecting on a balanced basis in three core pillars: Business – Governance – Technology. As Dr. Binh emphasized during the meeting, it is the firm’s strategy to provide comprehensive solutions to meet global businesses and each individual’s most basic demands.
With customers varying from large private enterprises, SMEs to individuals, FPT thrives on accommodating each group with unique services, combining different technologies to enhance business management, administration, and most importantly, customer services at every touchpoint. This highlights the firm’s growth strategy based on data-driven operations, a customer-centric motto, and breakthrough technology solutions.
According to FPT CEO Nguyen Van Khoa, technology-wise, the firm will leverage on-trend technologies to provide world-class digital transformation solutions and realize breakthrough opportunities for its shareholders.
As Vietnam’s technology pioneer, FPT plans to invest heavily in core technologies such as AI, Cloud, Big Data, Blockchain, and Hyper Automation. The Made-by-FPT ecosystem is also targeted as FPT's key growth driver in the long term, with a revenue growth rate of 42.8% in 2021.
FPT sets its message for 2022 to be: “Determined to fight” and plans to innovate in business and sales activities, expand its customer base in all sizes and fields globally. Promoting a long-term sustainable growth strategy, the firm targets a 19% growth in revenue and 20.2% in profit before tax for the following year.
About FPT Corporation
FPT Corporation is a globally leading technology and IT services provider headquartered in Vietnam, with nearly US$1.6 billion in revenue and 37,000 employees. As a pioneer in digital transformation, FPT delivers world-class services in Smart factories, Digital platforms, RPA, AI, IoT, Enterprise Mobility, Cloud, AR/VR, Business Applications, Application Services, BPO, and so on. The company has served over 1000+ customers worldwide, 85 of which are Fortune Global 500 companies in Aerospace & Aviation, Automotive, Banking and Finance, Logistics & Transportation, Utilities, and more. For more information, please visit www.fpt-software.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005158/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom